Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

University Hospital Gasthuisberg, Leuven, Belgium

Chantal Mathieu is a physician-scientist who has contributed to the field of diabetes and endocrinology through basic and clinical research. 

Her work in animal models of type 1 diabetes established 1,25-dihydroxyvitamin D3 as an immune modulator and demonstrated the potential of Lactococcus Lactis as a carrier tool for peptides and proteins, which became the basis for a worldwide clinical trial in people with newly diagnosed type 1 diabetes. 


Her research group was amongst the first to demonstrate the relevance of post-translational modifications of beta-cell peptides and proteins in autoantigen generation in murine and human type 1 diabetes. Prof. Mathieu’s clinical work involving new products and treatment paradigms in diabetes, such as new insulins, adjunct therapies and diagnosis of gestational diabetes as well as her educational skills have made her a prominent speaker in international fora. 


She has promoted shared-care, positioning of diabetes education and reimbursement of novel technologies. Prof. Mathieu is co-author of several consensus papers, including the 2018-19 ADA/EASD Consensus on glucose lowering therapies in type 2 diabetes. Prof. Mathieu leads the INNODIA project and established its Patient Advisory Committee. Prof. Mathieu is also (senior) vice-president of EASD, Chair of postgraduate education and Chair of the European Diabetes Forum.

Christophe De Block - Speaker

Christophe De Block

University of Antwerp, Antwerp, Belgium

Christophe De Block is the Head of the Department of Endocrinology, Diabetology and Metabolism and Professor at the University of Antwerp and former President of the Diabetes Liga Belgium. Prof. De Block’s main clinical and research interests are related to prediction and prevention of type 1 diabetes, autoimmune polyendocrine syndromes and new treatment options for diabetes. 


His latest field of interest focuses on the application of continuous glucose monitoring, functional insulin therapy and sensor-augmented pump therapy. Professor De Block has received several scientific awards, including the Award of the Royal Academy of Medicine of Belgium for experimental investigations on autoimmune diseases, the Young Investigator’s Award of the Diabetes and Nutrition Study Group 2003, the Young Investigator’s Award of the Belgian Endocrine Society in 2005 and the Novo Nordisk Award for Diabetes 2015-2016. 


He has published more than 120 papers in international medical journals and is a member of the Editorial Board of Current Diabetes Reviews. Prof. De Block is a member of the European Association for the Study of Diabetes (EASD), the American Diabetes Association (ADA), the Endocrine Society, the Belgian Diabetes Registry and the Belgian Endocrine Society.

Read full bio
Andreas Liebl - Speaker

Andreas Liebl

Fachklinik , Bad Heilbrunn, Germany

Andreas Liebl is Medical Director of the Center for Diabetes and Metabolism at the Fachklinik in Bad Heilbrunn, Germany. 

His research interests include insulin therapy, pharmacoeconomics, insulin pump therapy, intraperitoneal insulin therapy, continuous glucose monitoring and other diabetes technology. He is an advisor for the German Health Authorities and Payers Organisations. Dr. Liebl has been a board member of ‘Diabetes Technology – Insulin Pumps and Glucose Sensors’ AGDT, which is a working group of the German Diabetes Association (DDG). 


He is also Past-Chairman and current board member of the Diabetes Expert Commission FKDB within the DDG. Dr. Liebl is author or co-author of more than 100 national and international publications and has delivered numerous presentations at scientific meetings all over the world.

Read full bio